Literature DB >> 10372931

Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors.

S Savastano1, D Miotto, G Casarrubea, S Teso, M Chiesura-Corona, G P Feltrin.   

Abstract

We evaluated factors affecting long-term survival after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) complicating cirrhosis. One hundred eighty-two patients with Child's class A or B cirrhosis and an HCC, not amenable to surgery or percutaneous ethanol injection, underwent 346 TACEs (mean 1.9) with epirubicin, iodized oil, and gelatin sponge. Many prognostic factors were subjected to univariate analysis and thereafter, when significant, to the Cox's hazard proportional model. Finally, the significant indices in the Cox's model were used to estimate the accuracy of the probability of death with computation of the area under the receiving operative characteristic (ROC) curve. The cumulative survival rates at 1, 2, 3, and 5 years were 0.83, 0.52, 0.40, and 0.16, respectively. According to Cox's model, the factors associated with significantly worse survival were the presence of ascites (p = 0.0027), elevated bilirubin levels (p = 0.0163), elevated alpha-fetoprotein (alphaFP) values (p = 0.0067), a tumor greater than 5 cm in diameter (p = 0.0001), and the absence of a tumor capsule-like rim (p = 0.0278). According to these parameters, the accuracy of the probability of death estimated with ROC analysis was 0.63. Minor and major complications occurred in 82 patients (45%) and caused death in 2 patients. Long-term prognosis after TACE for HCCs in patients with Child's class A or B cirrhosis depends on the presence of ascites, the bilirubin level, the alphaFP value, the diameter of the tumor, and the presence of a tumor capsule-like rim. However, when considered altogether, these variables are poor predictors to evaluate survival, and other factors should be investigated to identify subjects more responsive to TACE. Complications occur in a high percentage of patients, but they do not affect long-term prognosis.

Entities:  

Mesh:

Year:  1999        PMID: 10372931     DOI: 10.1097/00004836-199906000-00010

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  22 in total

1.  Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?

Authors:  Koichiro Yamakado; Shiro Miyayama; Shozo Hirota; Kimiyoshi Mizunuma; Kenji Nakamura; Yoshitaka Inaba; Akihiro Maeda; Kunihiro Matsuo; Norifumi Nishida; Takeshi Aramaki; Hiroshi Anai; Shinichi Koura; Shigeo Oikawa; Ken Watanabe; Taku Yasumoto; Kinya Furuichi; Masato Yamaguchi
Journal:  Jpn J Radiol       Date:  2012-05-30       Impact factor: 2.374

2.  Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Authors:  Chuan Chen; Dong-Ping Chen; Yan-Yan Gu; Liang-Hao Hu; Dan Wang; Jin-Huan Lin; Zhao-Shen Li; Jing Xu; Ge Wang
Journal:  Tumour Biol       Date:  2015-04-02

3.  Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.

Authors:  Jun Qian; Elsie Oppermann; Andreas Tran; Ulli Imlau; Kun Qian; Thomas Josef Vogl
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

4.  Quantitative analysis of plasma HBV DNA for early evaluation of the response to transcatheter arterial embolization for HBV-related hepatocellular carcinoma.

Authors:  Ying-Wen Su; Yu-Wen Huang; Sheng-Hsuan Chen; Chin-Yuan Tzen
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

5.  Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma.

Authors:  Trevor W Reichman; Phil Bahramipour; Alison Barone; Baburao Koneru; Adrian Fisher; Daniel Contractor; Dorian Wilson; Andrew Dela Torre; Kyunghee C Cho; Arun Samanta; Lawrence E Harrison
Journal:  J Gastrointest Surg       Date:  2005 May-Jun       Impact factor: 3.452

6.  Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation.

Authors:  Mike-S-L Liem; Ronnie-T-P Poon; Chung-Mau Lo; Wai-Kuen Tso; Sheung-Tat Fan
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

7.  Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma.

Authors:  Wei-Jian Guo; Er-Xin Yu; Lu-Ming Liu; Jie Li; Zhen Chen; Jun-Hua Lin; Zhi-Qiang Meng; Yi Feng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

8.  Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization.

Authors:  Eun Sun Jang; Jung-Hwan Yoon; Jin Wook Chung; Eun Ju Cho; Su Jong Yu; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-03       Impact factor: 4.553

9.  Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China.

Authors:  Ming Shi; Ji-An Chen; Xiao-Jun Lin; Rong-Ping Guo; Yun-Fei Yuan; Min-Shan Chen; Ya-Qi Zhang; Jin-Qing Li
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

10.  Unresectable hepatocellular carcinoma treated with transarterial chemoembolization: clinical data from a single teaching hospital.

Authors:  Youhui Wang; Yanping Shen
Journal:  Int J Clin Exp Med       Date:  2013-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.